Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Stopped No subjects were eligible for the study. The study closed on 07-15-2021.

Conditions

• Pulmonary Neuroendocrine Neoplasm
• Pheochromocytoma
• Paraganglioma
• Thymus Carcinoid
• Unknown Primary Tumors
• Neuroendocrine Tumors
• Neuroendocrine Skin Carcinoma
• Neuroendocrine Breast Tumor
• Neuroendocrine Carcinoma Metastatic
• Neuroendocrine Neoplasm of Ovary

Interventions

• DRUG: 177Lu-DOTATOC

Sponsor

Excel Diagnostics and Nuclear Oncology Center